1-2 of 2
Philippe Rousselot
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax

Antoine Pinton, Lucien Courtois, Charlotte Doublet, Aurélie Cabannes-Hamy, Guillaume Andrieu, Charlotte Smith, Estelle Balducci, Agata Cieslak, Aurore Touzart, Mathieu Simonin, Véronique Lhéritier, Françoise Huguet, Marie Balsat, Hervé Dombret, Philippe Rousselot, Salvatore Spicuglia, Elizabeth Macintyre, Nicolas Boissel, Vahid Asnafi
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 94–105.
https://doi.org/10.1158/1078-0432.CCR-23-2159
Published: 05 January 2024
View articletitled, PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Open the PDF for PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax in another window
Includes: Supplementary data
Journal Articles

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Franck Emmanuel Nicolini, Stéphanie Dulucq, Lisa Boureau, Pascale Cony-Makhoul, Aude Charbonnier, Martine Escoffre-Barbe, Françoise Rigal-Huguet, Valérie Coiteux, Bruno Varet, Viviane Dubruille, Pascal Lenain, Philippe Rousselot, Delphine Rea, Agnès Guerci-Bresler, Laurence Legros, Jixing Liu, Martine Gardembas, Jean-Christophe Ianotto, Pascal Turlure, Hyacinthe Johnson-Ansah, Juliana Martiniuc, Henry Jardel, Bertrand Joly, Patricia Zunic, Tawfiq Henni, Bruno Villemagne, Marc G. Berger, Emilie Cayssials, François Guilhot, Fabrice Larosa, Joëlle Guilhot, Gabriel Etienne, François-Xavier Mahon
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6606–6613.
https://doi.org/10.1158/1078-0432.CCR-18-3373
Published: 15 November 2019
View articletitled, Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
Open the PDF for Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients in another window
Includes: Supplementary data